Antibody molecules which bind il-17a and il-17f

Abstract

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

1 .- 6 . (canceled) 
     
     
         7 . An antibody or antigen-binding fragment thereof which binds human IL-17A and human IL-17F and comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2, the sequence given in SEQ ID NO:6 for CDR-L3, the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2, and the sequence given in SEQ ID NO:3 for CDR-H3. 
     
     
         8 . The antibody or antigen-binding fragment thereof according to  claim 7 , which is a complete antibody molecule having full length heavy and light chains. 
     
     
         9 . The antibody or antigen-binding fragment thereof according to  claim 7 , which is an antigen-binding antibody fragment. 
     
     
         10 . The antigen-binding fragment according to  claim 9 , which is a Fab, Fab′, F(ab′) 2 , scFv, or Fv fragment. 
     
     
         11 . The antibody according to claim  1 , wherein the antibody is a multi-specific antibody. 
     
     
         12 . A pharmaceutical composition comprising the antibody according to  claim 8 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. 
     
     
         13 . A pharmaceutical composition comprising the antigen-binding fragment of  claim 9 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. 
     
     
         14 . A method of reducing the effect of IL-17A and/or IL-17F in vivo, the method comprising administering to a subject the antibody of  claim 8 . 
     
     
         15 . The method of  claim 14 , wherein the subject is suffering from endotoxic shock associated with infection, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive pulmonary disease (COPD), acute lung injury, pelvic inflammatory disease, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, Ulcerative colitis, Castleman's disease, a spondyloarthropathy, dermatomyositis, myocarditis, uveitis, exophthalmos, autoimmune thyroiditis, Peyronie's Disease, coeliac disease, gallbladder disease, psoriasis, atopic dermatitis, vasculitis, surgical adhesions, stroke, autoimmune diabetes, Type I Diabetes, lyme arthritis, immune mediated inflammatory disorders of the central and peripheral nervous system, an autoimmune disorder, pancreatitis, trauma, graft-versus-host disease, transplant rejection, pulmonary fibrosis, liver fibrosis, renal fibrosis, scleroderma, systemic sclerosis, heart disease, intravascular coagulation, bone resorption, osteoporosis, periodontitis or hypochlorhydia. 
     
     
         16 . The method of  claim 15 , wherein the heart disease is myocardial infarction or atherosclerosis. 
     
     
         17 . The method of  claim 15 , wherein the autoimmune disorder is an autoimmune inflammatory disorder of the central or peripheral nervous system. 
     
     
         18 . The method of  claim 17 , wherein the autoimmune inflammatory disorder of the central or peripheral nervous system is multiple sclerosis or Guillain-Barr syndrome. 
     
     
         19 . The method of  claim 15 , wherein the spondyloarthropathy is ankylosing spondylitis. 
     
     
         20 . A method for treating rheumatoid arthritis, psoriatic arthritis, asthma, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, Ulcerative colitis, psoriasis or a spondyloarthropathy in a subject, the method comprising administering to a subject in need thereof the antibody of  claim 8 . 
     
     
         21 . A method of reducing the effect of IL-17A and/or IL-17F in vivo, the method comprising administering to a subject the antigen-binding fragment of  claim 9 . 
     
     
         22 . The method of  claim 21 , wherein the subject is suffering from endotoxic shock associated with infection, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive pulmonary disease (COPD), acute lung injury, pelvic inflammatory disease, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, Ulcerative colitis, Castleman's disease, a spondyloarthropathy, dermatomyositis, myocarditis, uveitis, exophthalmos, autoimmune thyroiditis, Peyronie's Disease, coeliac disease, gallbladder disease, psoriasis, atopic dermatitis, vasculitis, surgical adhesions, stroke, autoimmune diabetes, Type I Diabetes, lyme arthritis, immune mediated inflammatory disorders of the central and peripheral nervous system, an autoimmune disorder, pancreatitis, trauma, graft-versus-host disease, transplant rejection, pulmonary fibrosis, liver fibrosis, renal fibrosis, scleroderma, systemic sclerosis, heart disease, intravascular coagulation, bone resorption, osteoporosis, periodontitis or hypochlorhydia. 
     
     
         23 . The method of  claim 22 , wherein the heart disease is myocardial infarction or atherosclerosis. 
     
     
         24 . The method of  claim 22 , wherein the autoimmune disorder is an autoimmune inflammatory disorder of the central or peripheral nervous system. 
     
     
         25 . The method of  claim 24 , wherein the autoimmune inflammatory disorder of the central or peripheral nervous system is multiple sclerosis or Guillain-Barr syndrome. 
     
     
         26 . The method of  claim 22 , wherein the spondyloarthropathy is ankylosing spondylitis. 
     
     
         27 . A method for treating rheumatoid arthritis, psoriatic arthritis, asthma, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, Ulcerative colitis, psoriasis or a spondyloarthropathy in a subject, the method comprising administering to a subject in need thereof the antigen-binding fragment of  claim 9 . 
     
     
         28 . A composition comprising an expression vector encoding an antibody light chain variable region comprising the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2, and the sequence given in SEQ ID NO:6 for CDR-L3, and an expression vector comprising an antibody heavy chain variable region comprising the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2, and the sequence given in SEQ ID NO:3 for CDR-H3